Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G G Hermann

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Ugeskrift for Laeger|September 8, 1986
[Suprarenal cysts]P Bagi, G G Hermann, F Burcharth
Natural Immunity|January 1, 1992
LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell linesG G Hermann, J Zeuthen, M H Claësson
Scandinavian Journal of Urology and Nephrology|January 1, 1991
Intravesical BCG therapy in bladder carcinoma. Effect on cytotoxicity, IL-2 production and phenotype of peripheral blood mononuclear cellsG G Hermann, K R Petersen, J Zeuthen, et al.
The Journal of Urology|September 1, 1990
Low dose intravesical heparin as prophylaxis against recurrent noninvasive (stage Ta) bladder cancerM Bitsch, G G Hermann, J P Andersen, et al.
Journal of Clinical Immunology|November 1, 1990
Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cellsG G Hermann, K R Petersen, K Steven, et al.
The Journal of Urology|January 1, 1994
The in vitro cytotoxicity of urine from patients with interstitial cystitisR Beier-Holgersen, G G Hermann, S O Mortensen, et al.
Cytokine|March 1, 1992
In vitro production of TNF-alpha, IL-1 beta and IL-6 by mononuclear blood cells of patients with renal cell carcinoma undergoing rIL-2 treatment. Relation between clinical response and TNF-alpha productionG G Hermann, J Zeuthan, P F Geertsen, et al.
Cancer|April 15, 1984
Primary hemangiosarcoma of the spleen with angioscintigraphic demonstration of metastasesG G Hermann, J Fogh, N Graem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II studyP F Geertsen, G G Hermann, H von der Maase, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinomaG G Hermann, P F Geertsen, H von der Maase, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Ugeskrift for Laeger|September 8, 1986
[Suprarenal cysts]P Bagi, G G Hermann, F Burcharth
Natural Immunity|January 1, 1992
LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell linesG G Hermann, J Zeuthen, M H Claësson
Scandinavian Journal of Urology and Nephrology|January 1, 1991
Intravesical BCG therapy in bladder carcinoma. Effect on cytotoxicity, IL-2 production and phenotype of peripheral blood mononuclear cellsG G Hermann, K R Petersen, J Zeuthen, et al.
The Journal of Urology|September 1, 1990
Low dose intravesical heparin as prophylaxis against recurrent noninvasive (stage Ta) bladder cancerM Bitsch, G G Hermann, J P Andersen, et al.
Journal of Clinical Immunology|November 1, 1990
Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cellsG G Hermann, K R Petersen, K Steven, et al.
The Journal of Urology|January 1, 1994
The in vitro cytotoxicity of urine from patients with interstitial cystitisR Beier-Holgersen, G G Hermann, S O Mortensen, et al.
Cytokine|March 1, 1992
In vitro production of TNF-alpha, IL-1 beta and IL-6 by mononuclear blood cells of patients with renal cell carcinoma undergoing rIL-2 treatment. Relation between clinical response and TNF-alpha productionG G Hermann, J Zeuthan, P F Geertsen, et al.
Cancer|April 15, 1984
Primary hemangiosarcoma of the spleen with angioscintigraphic demonstration of metastasesG G Hermann, J Fogh, N Graem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II studyP F Geertsen, G G Hermann, H von der Maase, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinomaG G Hermann, P F Geertsen, H von der Maase, et al.
Pageof 4